Kidney Cancer (RCC) Treatment in Lucknow
Targeted Therapy & Immunotherapy Expertise
Renal cell carcinoma (RCC) accounts for 85–90% of kidney cancers in adults. While incidence is lower in India compared to the West, patients often present at younger ages with more advanced disease. At Lucknow Cancer Institute, Dr. Sidharth Pant offers comprehensive RCC care including molecular profiling, targeted therapies (TKIs), and immunotherapy (IO) for optimal outcomes.
Global & Indian Epidemiology
Understanding RCC burden worldwide and in India
Global Epidemiology
- 14th most common cancer globally
- ASIR: 4.6/100,000 (men 6.1, women 3.2)
- Highest incidence: North America/Europe (15–20/100,000)
- Incidence rose from 160k (1990) to 390k (2021)
- 5-year survival: 75% localized, 14% metastatic
India Epidemiology
- 85–90% of kidney tumors are RCC
- Incidence: males ~2/100,000, females ~1/100,000
- 14th/15th leading cancer cause in India
- Younger onset: median 55–58 years vs 65 in West
- M:F ratio: 3:1
- Advanced presentation: 60–65% metastatic vs 30–40% West
- Only 35–40% stage I–II at diagnosis
- Northeast India shows higher rates
- Clear cell: 68–85% of cases in India
Critical Alert for India
Rising trend with increasing obesity and smoking rates in India. Early detection is challenging as 60–65% present with metastatic disease compared to 30–40% in Western countries.
Major Risk Factors
Understanding what increases RCC risk
Established Risk Factors
Smoking (Strongest Risk)
Dose‑dependent relationship; smokers have 2–3× higher risk
Obesity
24% increased risk per 5 kg/m² BMI increase
Hypertension
Chronic hypertension increases RCC risk
Family History
von Hippel‑Lindau syndrome and other hereditary conditions
Prevention & Screening
- No routine screening recommended for average-risk individuals
- Smoking cessation significantly reduces risk
- Weight management and blood pressure control
- Genetic counseling for family history of RCC or VHL syndrome
- High-risk individuals (VHL, hereditary papillary RCC) may require periodic imaging
At Lucknow Cancer Institute
Genetic counseling available for patients with family history of kidney cancer or suspected hereditary syndromes.
RCC Subtypes & Staging
Understanding RCC classification and prognosis
RCC Subtypes
Clear Cell RCC
Most common subtype; VHL gene mutations; responds well to targeted therapies
Papillary RCC
Type 1 (hereditary) and Type 2; different genetic alterations
Chromophobe RCC
Better prognosis; less aggressive behavior
TNM Staging & Survival
| Stage | Description | 5-Year Survival |
|---|---|---|
| Stage I | Tumor ≤7 cm, confined to kidney | 80–95% |
| Stage II | Tumor >7 cm, confined to kidney | 70–80% |
| Stage III | Regional spread (veins, lymph nodes) | 40–60% |
| Stage IV | Distant metastasis | 10–20% |
Symptoms & Diagnosis
Recognizing RCC and diagnostic work-up
Symptoms & Presentation
Classic Triad Present in Only 10%
Hematuria + Flank pain + Mass = Only 10% of cases. Most RCC is discovered incidentally on imaging for other reasons.
Paraneoplastic Syndromes (56%)
- Anemia (normocytic, normochromic)
- Fever of unknown origin
- Hypercalcemia
- Polycythemia
- Stauffer syndrome (liver dysfunction)
Diagnostic Work-up
Imaging
Contrast-enhanced CT abdomen (gold standard) • MRI for complex cases • Ultrasound for initial evaluation
Biopsy
CT/USG-guided biopsy for advanced/metastatic disease • Not routinely needed for resectable tumors
Staging
Chest CT for lung metastases • Bone scan if symptomatic • Brain imaging if neurological symptoms
At Lucknow Cancer Institute
Multiparametric MRI expertise for complex renal masses • Molecular profiling for advanced RCC to guide targeted therapy selection.
Comprehensive Treatment
Stage-specific RCC management
Localized RCC (Stage I-III)
Surgical Options:
- Partial nephrectomy (nephron-sparing surgery) for tumors ≤7 cm
- Radical nephrectomy for larger tumors or central location
- Laparoscopic approach (71% of cases) - less invasive
- Robotic surgery for complex partial nephrectomies
Adjuvant Therapy:
- Consider adjuvant pembrolizumab for high-risk clear cell RCC
- Observation for low-risk tumors
Advanced RCC (Stage IV)
First-line Therapy:
- Immunotherapy + TKI: Nivolumab + cabozantinib (preferred)
- Dual immunotherapy: Nivolumab + ipilimumab (IMDC intermediate/poor risk)
- TKI monotherapy: Sunitinib, pazopanib (selected cases)
IMDC Risk Stratification:
- Favorable: 0 risk factors
- Intermediate: 1-2 risk factors
- Poor: ≥3 risk factors
Second-line & Beyond:
- TKI switch (lenvatinib + everolimus)
- Cabozantinib monotherapy
- Clinical trial participation
Treatment at Lucknow Cancer Institute
RCC molecular profiling to identify therapeutic targets • TKI/IO access with all modern targeted therapies available • IMDC risk stratification for personalized treatment selection • Clinical trial access for refractory cases.